TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study of the Use of Human Milk Cream as a Caloric Supplement in a Subset of Very Low Birth Weight Pre-Term Infants
Brief Summary: Human milk is commonly considered to have 20 calories per ounce (kcal/oz). However, studies show that up to 65% of human milk may be less than the expected 20 kcal/oz which can greatly affect an infant's growth. The investigators now have the ability to measure caloric density of human milk and add human milk cream to any human milk (mother's own or donor human milk) that is less than 20 kcal/oz to bring it up to that amount.


Options:
A: Arm Label: Individualized fortification of breast milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Individualized fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Individualized fortification of breast milk; Assigned to Arm(s): Individualized fortification of breast milk
B: Arm Label: Human Milk Cream Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Human Milk Cream | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Human Milk Cream; Assigned to Arm(s): Human Milk Cream Group
C: Arm Label: Standard Protein Group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard fortification | Arm Label: Enhanced Protein Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein supplementation, Dietary Supplement: Standard fortification | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein supplementation; Assigned to Arm(s): Enhanced Protein Group | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard fortification; Assigned to Arm(s): Enhanced Protein Group, Standard Protein Group
D: Arm Label: Experimental Human Milk Fortifier; Type: EXPERIMENTAL; Interventions: Other: Experimental human milk fortifier | Arm Label: Control Human Milk Fortifier; Type: ACTIVE_COMPARATOR; Interventions: Other: Control human milk fortifier | Intervention Type: OTHER; Name: Experimental human milk fortifier; Assigned to Arm(s): Experimental Human Milk Fortifier | Intervention Type: OTHER; Name: Control human milk fortifier; Assigned to Arm(s): Control Human Milk Fortifier

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Efficacy, Safety and Pharmacokinetic Study on the Short-term and Long-term Use of Metformin in Obese Children and Adolescents
Brief Summary: The purpose of this study is to determine whether metformin is effective in reducing BMI and insulin resistance in obese children and adolescents.


Options:
A: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Behavioral: Lifestyle intervention | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Lifestyle intervention | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Metformin, Placebo
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin (glucophage) | Arm Label: Oral Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: oral placebo | Intervention Type: DRUG; Name: Metformin (glucophage); Assigned to Arm(s): Metformin | Intervention Type: OTHER; Name: oral placebo; Assigned to Arm(s): Oral Placebo
C: Arm Label: Exenatide, then Open-Label Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Placebo, then Open Label Exenatide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Exenatide, Drug: Placebo | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide, then Open-Label Exenatide, Placebo, then Open Label Exenatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, then Open Label Exenatide
D: Arm Label: Sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lead-in sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Sibutramine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Lead-in sibutramine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Evaluating the Effects of [Vortioxetine] Lu AA21004 Versus Agomelatine in Adult Patients Suffering From Major Depressive Disorder With Inadequate Response to Antidepressant Treatment
Brief Summary: The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin Reuptake Inhibitors (SRI) antidepressants.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine (Lu AA21004) 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Vortioxetine (Lu AA21004) 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Venlafaxine XL 225 mg; Type: OTHER; Interventions: Drug: Venlafaxine XL | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine (Lu AA21004) 10 mg, Vortioxetine (Lu AA21004) 5 mg | Intervention Type: DRUG; Name: Venlafaxine XL; Assigned to Arm(s): Venlafaxine XL 225 mg
B: Arm Label: Vortioxetine 10 mg or 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Agomelatine 25 mg or 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Agomelatine | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine 10 mg or 20 mg | Intervention Type: DRUG; Name: Agomelatine; Assigned to Arm(s): Agomelatine 25 mg or 50 mg
C: Arm Label: Vortioxetine (Lu AA21004); Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Venlafaxine extended release; Type: ACTIVE_COMPARATOR; Interventions: Drug: Venlafaxine extended release | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine (Lu AA21004) | Intervention Type: DRUG; Name: Venlafaxine extended release; Assigned to Arm(s): Venlafaxine extended release
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Vortioxetine 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Duloxetine 60 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Vortioxetine; Assigned to Arm(s): Vortioxetine 15 mg, Vortioxetine 20 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Evaluating the Effects of [Vortioxetine] Lu AA21004 Versus Agomelatine in Adult Patients Suffering From Major Depressive Disorder With Inadequate Response to Antidepressant Treatment
Brief Summary: The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin Reuptake Inhibitors (SRI) antidepressants.


Options:
A: Arm Label: Vortioxetine 10 mg or 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Agomelatine 25 mg or 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Agomelatine | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine 10 mg or 20 mg | Intervention Type: DRUG; Name: Agomelatine; Assigned to Arm(s): Agomelatine 25 mg or 50 mg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ziprasidone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Brexpiprazole + ADT; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole +ADT | Arm Label: Placebo + ADT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Placebo + ADT | Intervention Type: DRUG; Name: Brexpiprazole +ADT; Assigned to Arm(s): Brexpiprazole + ADT
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cariprazine 1-2 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 2-4.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 1-2 mg, Cariprazine 2-4.5 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Trial of Cetuximab and Dasatinib in Patients With Cetuximab-resistant, Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck and Low Serum IL-6
Brief Summary: This is a single-arm, non-masked, open-label, Phase II study of cetuximab + dasatinib in recurrent Squamous Cell Carcinoma of The Head and Neck (SCCHN) that has recurred after cetuximab-containing therapy (please see attached schema).

The primary endpoint 12-week PFS.


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Dasatinib + Placebo | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib plus Dasatinib | Arm Label: Arm D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Dasatinib + Placebo; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Erlotinib plus Dasatinib; Assigned to Arm(s): Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm D | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A
B: Arm Label: Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab | Arm Label: Pembrolizumab Q2W; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Pembrolizumab Q3W; Type: ACTIVE_COMPARATOR; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab Q2W, Pembrolizumab Q3W | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab
C: Arm Label: CETUXIMAB AND DASATINIB; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: Dasatinib | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): CETUXIMAB AND DASATINIB | Intervention Type: DRUG; Name: Dasatinib; Assigned to Arm(s): CETUXIMAB AND DASATINIB
D: Arm Label: postop chemoradio with cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Radiation: chemoradiotherapy with cisplatin | Arm Label: postop chemoradio (cisplatin)+gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Iressa (Gefitinib) | Intervention Type: DRUG; Name: Iressa (Gefitinib); Assigned to Arm(s): postop chemoradio (cisplatin)+gefitinib | Intervention Type: RADIATION; Name: chemoradiotherapy with cisplatin; Assigned to Arm(s): postop chemoradio with cisplatin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose is to determine if the consumption of study product has an effect on acute respiratory infections and/or diarrheal disease.


Options:
A: Arm Label: 1 = Tested product; Type: ACTIVE_COMPARATOR; Interventions: Other: 1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®) | Arm Label: 2 = Control product; Type: SHAM_COMPARATOR; Interventions: Other: 2-Non fermented dairy product (control) | Intervention Type: OTHER; Name: 1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®); Assigned to Arm(s): 1 = Tested product | Intervention Type: OTHER; Name: 2-Non fermented dairy product (control); Assigned to Arm(s): 2 = Control product
B: Arm Label: fermented milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fermented milk | Arm Label: fermented rice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fermented rice | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: fermented milk; Assigned to Arm(s): fermented milk | Intervention Type: DIETARY_SUPPLEMENT; Name: fermented rice; Assigned to Arm(s): fermented rice
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Modified formula (MFGM-enriched formula with reduced energy and protein content) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Modified formula (MFGM-enriched formula with reduced energy and protein content); Assigned to Arm(s): 1
D: Arm Label: Cow's Milk; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cow's milk | Arm Label: Follow-On Formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Follow-On Formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Cow's milk; Assigned to Arm(s): Cow's Milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Follow-On Formula; Assigned to Arm(s): Follow-On Formula

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose is to determine if the consumption of study product has an effect on acute respiratory infections and/or diarrheal disease.


Options:
A: Arm Label: Bifidobacterium animalis subsp. lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium animalis subsp. lactis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium animalis subsp. lactis; Assigned to Arm(s): Bifidobacterium animalis subsp. lactis
B: Arm Label: Cow's Milk; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cow's milk | Arm Label: Follow-On Formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Follow-On Formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Cow's milk; Assigned to Arm(s): Cow's Milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Follow-On Formula; Assigned to Arm(s): Follow-On Formula
C: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: low calcium milk of 180 ml | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: regular milk of 180 ml | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: regular milk of 180 ml + probiotics | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: regular milk of 180 ml + probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: low calcium milk of 180 ml; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: regular milk of 180 ml; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: regular milk of 180 ml + probiotics; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: regular milk of 180 ml + probiotics; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Controlled, Randomized Clinical Trial of Nebulized Hypertonic Saline for Hospitalized Infants With Viral Bronchiolitis
Brief Summary: The purpose of this study is to determine if nebulized hypertonic saline (or extra salty water mist) helps infants less than 12 months old hospitalized with bronchiolitis (or bad chest colds) get better enough to be discharged from the hospital sooner than those infants given nebulized normal saline (or regular salty water mist).


Options:
A: Arm Label: Nebulized Hypertonic Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% sodium chloride | Arm Label: Nebulized Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% sodium chloride | Intervention Type: DRUG; Name: 3% sodium chloride; Assigned to Arm(s): Nebulized Hypertonic Saline | Intervention Type: DRUG; Name: 0.9% sodium chloride; Assigned to Arm(s): Nebulized Normal Saline
B: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% Normal Saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% Normal Saline; Assigned to Arm(s): Nebulized 0.9% Normal Saline
C: Arm Label: Treatment 1. 5% Saline + Epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Treatment 1. (5% Hypertonic saline + Epinephrine) | Arm Label: Treatment 3. 3% Saline + Epinephrine; Type: OTHER; Interventions: Drug: Treatment 3. (3% Hypertonic saline + Epinephrine) | Arm Label: Treatment 2 . 0.9% Saline + Epinephrine; Type: OTHER; Interventions: Drug: Treatment 2. (Normal saline + Epinephrine) | Intervention Type: DRUG; Name: Treatment 1. (5% Hypertonic saline + Epinephrine); Assigned to Arm(s): Treatment 1. 5% Saline + Epinephrine | Intervention Type: DRUG; Name: Treatment 3. (3% Hypertonic saline + Epinephrine); Assigned to Arm(s): Treatment 3. 3% Saline + Epinephrine | Intervention Type: DRUG; Name: Treatment 2. (Normal saline + Epinephrine); Assigned to Arm(s): Treatment 2 . 0.9% Saline + Epinephrine
D: Arm Label: hypertonic saline and usual care; Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Arm Label: usual care (oxygen therapy); Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Intervention Type: DEVICE; Name: 3% hypertonic saline; Assigned to Arm(s): hypertonic saline and usual care, usual care (oxygen therapy)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Controlled, Randomized Clinical Trial of Nebulized Hypertonic Saline for Hospitalized Infants With Viral Bronchiolitis
Brief Summary: The purpose of this study is to determine if nebulized hypertonic saline (or extra salty water mist) helps infants less than 12 months old hospitalized with bronchiolitis (or bad chest colds) get better enough to be discharged from the hospital sooner than those infants given nebulized normal saline (or regular salty water mist).


Options:
A: Arm Label: Nebulized Hypertonic Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% sodium chloride | Arm Label: Nebulized Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% sodium chloride | Intervention Type: DRUG; Name: 3% sodium chloride; Assigned to Arm(s): Nebulized Hypertonic Saline | Intervention Type: DRUG; Name: 0.9% sodium chloride; Assigned to Arm(s): Nebulized Normal Saline
B: Arm Label: Standard Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: L-Epinephrine and Normal Saline (0.9%) | Arm Label: Study Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-Epinephrine and Hypertonic Saline (3%) | Intervention Type: DRUG; Name: L-Epinephrine and Normal Saline (0.9%); Assigned to Arm(s): Standard Treatment | Intervention Type: DRUG; Name: L-Epinephrine and Hypertonic Saline (3%); Assigned to Arm(s): Study Treatment
C: Arm Label: Normal saline and epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Normal saline and epinephrine | Arm Label: Hypertonic saline and epinephrine; Type: EXPERIMENTAL; Interventions: Drug: Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Hypertonic saline and epinephrine; Assigned to Arm(s): Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Normal saline and epinephrine; Assigned to Arm(s): Normal saline and epinephrine
D: Arm Label: Treatment 1. 5% Saline + Epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Treatment 1. (5% Hypertonic saline + Epinephrine) | Arm Label: Treatment 3. 3% Saline + Epinephrine; Type: OTHER; Interventions: Drug: Treatment 3. (3% Hypertonic saline + Epinephrine) | Arm Label: Treatment 2 . 0.9% Saline + Epinephrine; Type: OTHER; Interventions: Drug: Treatment 2. (Normal saline + Epinephrine) | Intervention Type: DRUG; Name: Treatment 1. (5% Hypertonic saline + Epinephrine); Assigned to Arm(s): Treatment 1. 5% Saline + Epinephrine | Intervention Type: DRUG; Name: Treatment 3. (3% Hypertonic saline + Epinephrine); Assigned to Arm(s): Treatment 3. 3% Saline + Epinephrine | Intervention Type: DRUG; Name: Treatment 2. (Normal saline + Epinephrine); Assigned to Arm(s): Treatment 2 . 0.9% Saline + Epinephrine

Answer: A